Cell and Gene Therapy Insights Volume 12 Issue 2

CELL AND GENE THERAPY INSIGHTS

Volume 12 Issue 2

Cell and Gene Therapy Insights Volume 12 Issue 2

Download PDF

Featuring

Issue Spotlight: Gene therapy analytics/CMC
Supply Chain focus: Raw and Starting Materials
Other articles
Webinars

Gene therapy analytics/CMC

Srivatsan Ramesh

Guest Editor:

Srivatsan Ramesh, Scientist at BridgeBio

Foreword

Engineering confidence in the next era of AAV-based gene therapy

Engineering confidence in the next era of AAV-based gene therapy

Srivatsan Ramesh

Viewpoint

Unraveling the analytical bottlenecks in AAV characterization: the transformative promise of NGS

Unraveling the analytical bottlenecks in AAV characterization: the transformative promise of NGS

Prateek Tripathi

From dose quantity to dose quality: elevating rAAV genome integrity as a CMC attribute

From dose quantity to dose quality: elevating rAAV genome integrity as a CMC attribute

XuShan Wang, Sarah M Richer, Beverly A Heinz

Next-generation strategies for managing AAV pre-existing immunity: beyond standard companion diagnostics

Next-generation strategies for managing AAV pre-existing immunity: beyond standard companion diagnostics

Katherine Block

Raw and Starting Materials

Viewpoint

Building confidence in cell and gene therapy: USP’s role in an evolving therapeutic frontier

Building confidence in cell and gene therapy: USP’s role in an evolving therapeutic frontier

articles

Editorial

Editor’s picks: exploring in vivo cell and gene therapies

Editor’s picks: exploring in vivo cell and gene therapies

Abigail Pinchbeck

Innovator Insight

Choosing a biomanufacturing service organization: from the BSO perspective

Choosing a biomanufacturing service organization: from the BSO perspective

R Thevi Guntnur, R Rendon III, J Higdon et al.

Uncovering CAR-T and CAR-NK cell potency using multi-analyte profiling

Uncovering CAR-T and CAR-NK cell potency using multi-analyte profiling

Jessica Fiege, Valeriu Bortnov

Genomic integrity and safety assessment strategies for CRISPR-edited cell therapies

Genomic integrity and safety assessment strategies for CRISPR-edited cell therapies

Stephanie Cherqui, Kurt Marshall

Advancing non-viral CAR-NK development: LNP engineering insights and cell therapy regulatory trends

Advancing non-viral CAR-NK development: LNP engineering insights and cell therapy regulatory trends

Sandy Tretbar, PhD, Limin Wang, PhD, RAC

Frozen by design: engineering and automating cryogenic storage to avoid risk and scale-up surprises

Frozen by design: engineering and automating cryogenic storage to avoid risk and scale-up surprises

P Terreni, M Jayawardena, P Walters et al.

dPCR strategies for sensitive quantification and fragment size assessment of residual host cell DNA

dPCR strategies for sensitive quantification and fragment size assessment of residual host cell DNA

J Kul, A Mesihovic Karamitsos, M Vranes

Proactively mitigating contamination risk across the end-to-end cell therapy manufacturing workflow

Proactively mitigating contamination risk across the end-to-end cell therapy manufacturing workflow

Clinical-scale manufacturing of transposon-based CAR-T cells using next-generation electroporation

Clinical-scale manufacturing of transposon-based CAR-T cells using next-generation electroporation 

Shigeki Yagyu, PhD, Stefanie Muthel, PhD

}